Finance

Beta
Lists
BRM:FRA
Bristol-Myers Squibb Co
€49.40
+4.15%
(+1.97) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BRM...
Open
€48.52
High
€49.40
Low
€48.52
Mkt. cap
116.95B
Avg. vol.
566.00
Volume
100.00
52-wk high
€53.56
52-wk low
€36.65
No. of employees
32K
Open
€48.52
High
€49.40
Low
€48.52
Mkt. cap
116.95B
Avg. vol.
566.00
Volume
100.00
52-wk high
€53.56
52-wk low
€36.65
No. of employees
32K
News stories
From sources across the web
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
12.27B
12.22B
12.50B
11.49B
Cost of goods sold
3.36B
3.31B
3.51B
3.41B
Cost of revenue
3.36B
3.31B
3.51B
3.41B
Research and development expenses
2.26B
2.43B
2.56B
2.24B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
1.79B
2.09B
1.61B
Operating expense
4.78B
5.05B
5.47B
4.28B
Total operating expenses
8.14B
8.36B
8.98B
7.69B
Operating income
4.13B
3.86B
3.52B
3.80B
Other non operating income
399.00M
529.00M
544.00M
125.00M
EBT including unusual items
1.77B
3.11B
1.47B
3.24B
EBT excluding unusual items
4.22B
4.07B
3.86B
3.65B
Income tax expense
460.00M
919.00M
384.00M
561.00M
Effective tax rate
25.96%
29.51%
26.12%
17.32%
Other operating expenses
-
-
-
-
Net income
1.31B
2.20B
1.09B
2.68B
Net profit margin
10.68%
18.01%
8.69%
23.30%
Earnings per share
1.46
1.63
1.26
1.58
Interest and investment income
139.00M
161.00M
148.00M
104.00M
Interest expense
-485.00M
-482.00M
-432.00M
-406.00M
Net interest expenses
-346.00M
-321.00M
-284.00M
-302.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.12B
4.91B
4.54B
4.41B
Gain or loss from assets sale
-7.00M
-9.00M
-
-34.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer